Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-12-22

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)

View source ↗

Summary

FDA approved a supplemental application for a buprenorphine and naloxone product from PAI Holdings/PAI Pharma. The combination is used for treatment of opioid u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE)